Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent inactivated influenza vaccine + live attenuated varicella vaccine
- Development stage
- Unknown
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
This drug entry refers to the co-administration of two separate vaccines: a trivalent inactivated influenza vaccine (TIV, brand name Anflu) and a live attenuated varicella vaccine. The TIV, developed by Sinovac Biotech, is a split-virion vaccine containing 15 µg of hemagglutinin from three influenza strains: A/H1N1, A/H3N2, and B/Victoria. The varicella vaccine, developed by Sinovac (Dalian) Vaccine Technology, utilizes the Oka strain of the varicella-zoster virus. A Phase 4 clinical trial in China evaluated the safety and immunogenicity of administering these two vaccines simultaneously in healthy children aged 7 to 12 years, demonstrating that co-administration is non-inferior to separate administration and is well-tolerated.
- Brand names
- Anflu
- Other names
- trivalent inactivated influenza vaccine-Sinovac (Dalian) Vaccine Technology Co., Ltd.-VaricellaTIV + Varicella vaccineAnflu + Varicella vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on trivalent inactivated influenza vaccine + live attenuated varicella vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent inactivated influenza vaccine + live attenuated varicella vaccine.